GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Waste Data Preview
In 2024, GlaxoSmithKline Pharmaceuticals conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards. The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Waste Generated | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Waste Recovered | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Hazardous Waste Generated | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data.  a | Copy restricted. Please purchase to unlock this data. | 0000000 |
Non-Hazardous Waste Disposed | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Create your Tracenable account today and download up to 5 company datasets of your choice for free. No credit card required.
Verified Sources Behind GlaxoSmithKline Pharmaceuticals’s Waste Management Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore GlaxoSmithKline Pharmaceuticals’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.
Insights into GlaxoSmithKline Pharmaceuticals's Waste Treatment Practices
In 2024, GlaxoSmithKline Pharmaceuticals generated a total of 1,482 metric tonnes of waste. a
Of this amount, 90.54% of GlaxoSmithKline Pharmaceuticals's total waste generated was recovered through methods such as recycling, reuse, or composting, while 9.46% was disposed of through landfilling, incineration, or combustion. a
GlaxoSmithKline Pharmaceuticals's Waste Recovery Rate
How much of GlaxoSmithKline Pharmaceuticals's waste is recycled or recovered?
In 2024, GlaxoSmithKline Pharmaceuticals reported a total waste generation of 1,482 metric tonnes, of which 90.54% was recovered through recycling, reuse, or composting. This high recovery rate suggests that GlaxoSmithKline Pharmaceuticals has implemented strong circular economy practices and actively prioritizes sustainable waste management. a
Has GlaxoSmithKline Pharmaceuticals reduced its environmental waste footprint over time?
Since 2024, GlaxoSmithKline Pharmaceuticals's total waste generation has increased by 2.26%, which may reflect expanding operations, weaker material efficiency, or insufficient waste reduction efforts. a
Over the same period, GlaxoSmithKline Pharmaceuticals's waste recovery rate increased by 1.93%. a
GlaxoSmithKline Pharmaceuticals’s Waste Recovery vs. Disposal Over Time
- Total Waste Disposed
- Total Waste Recovered
Insights into GlaxoSmithKline Pharmaceuticals’s Generation of Hazardous and Non-Hazardous Waste
In 2024, GlaxoSmithKline Pharmaceuticals generated a total of 1,482 metric tonnes of waste. a
Of this amount, 11.43% of GlaxoSmithKline Pharmaceuticals's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment. 86.19% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls. The remaining 2.38% was either treated using unspecified methods or not clearly categorized. a
GlaxoSmithKline Pharmaceuticals’s Hazardous vs Non-Hazardous Waste Over Time
- Total Non-Hazardous Waste Generated
- Total Hazardous Waste Generated
How GlaxoSmithKline Pharmaceuticals reduced the environmental impact of its waste?
Since 2024, GlaxoSmithKline Pharmaceuticals's total waste generation has increased by 2.26%, which may reflect expanding operations, weaker material efficiency, or insufficient waste reduction efforts. a
Since 2024, GlaxoSmithKline Pharmaceuticals's hazardous waste generation has increased by 1.05%, indicating a potential rise in the use of harmful materials, process inefficiencies, or limited hazardous waste reduction strategies.. a
Overall, GlaxoSmithKline Pharmaceuticals has seen a recent increase in both total waste and hazardous waste, which may indicate growing operational pressures or insufficient controls on harmful materials. a